About Pluslife

Founded in 2017, Pluslife is advancing global healthcare with high-performance, cost-effective, and portable diagnostics that improve accessibility and health management for both humans and pets. Leveraging next-generation genetic technologies, we are building a reliable, easy-to-use testing ecosystem that redefines how people and animals access diagnostics.

Founded by top-tier national talents under China’s talent introduction program, Pluslife brings together a diverse team of professors, postdoctoral researchers, and professionals in diagnostics, protein engineering, and financial strategy, including CFA-certified individuals. Our facilities cover over 10,000 square meters, integrating offices, laboratories, and manufacturing sites.

The company has received multiple national honors, including Leading Entrepreneurial Talent and Team, Specialized and Innovative SME, High-Tech Enterprise, and the 2024 Healthcare CSR Model Enterprise.

Powered by proprietary RHAM technology, Pluslife has developed molecular POCT devices and test cards for major infectious diseases, respiratory and reproductive tract infections, and pathogens in companion animals. We have filed over 170 patent and certification applications, with more than 50 granted and 120 approved internationally. Our products are used across countries and regions worldwide.

Corporate Positioning

 

Empowering global healthcare with high-performance, cost-effective, and portable diagnostics, improving accessibility and health management for both humans and pets.

Technology Platform

Independently developed patented technology RHAM

——

Independently developed patented technology RHAM

——

RHAM technology effectively overcomes the shortcomings of non-specific amplification (LAMP), insufficient sensitivity (RPA), long reaction time (NASBA), insufficient compatibility and patent limitation (CRISPR) of similar isothermal amplification technologies, and truly achieves the landing of high sensitivity and high specificity nucleic acid POCT rapid detection.

Autonomous raw material enzyme

——

Autonomous raw material enzyme

——

All product raw materials are self-produced by enzymes, with a new generation of enzyme directed evolution platform and protein expression platform, which can achieve large-scale production of protein raw materials at the level of millions per month.

Autonomous POCT process&fully automated production line

——

Autonomous POCT process&fully automated production line

——

With independent patented technology, the entire production line is automated, and the testing reagent kit can reach a monthly production capacity of millions of people.

넳 넲